[5] Nowadays, eight polymorphic forms are known that are determined by different conformers,[6][7] which makes flufenamic acid unique among other low-molecular medicinal compounds.

[8][9] A fundamental feature of the structure of flufenamic acid, which has generated significant interest in the design and development of drugs,[10] is the presence of a trifluoromethyl group.

Compounds with fluorine-containing substituents are known to have promising chemical and biological properties,[11][12] since such groups often improve the pharmacokinetics and bioavailability of drugs.

[13] Studies have shown the promise of repositioning flufenamic acid and the use of drugs based on it in the treatment of Bartter syndrome.

The rate of gastrointestinal side effects can be as high as 60%,[17] manifested as at least one of the following: dyspepsia, nausea, abdominal pain and discomfort, constipation, diarrhoea, flatulence, indigestion, epigastric distress, stomatitits and anorexia.